NCT06331975 is a NA clinical trial of Radiomic signature in Non Small Cell Lung Cancer, sponsored by European Institute of Oncology.

Who is sponsoring NCT06331975?

NCT06331975 is sponsored by European Institute of Oncology.

What drugs are being tested in NCT06331975?

Interventions in NCT06331975: Radiomic signature.

What condition does NCT06331975 study?

NCT06331975 studies Non Small Cell Lung Cancer.

Is NCT06331975 still recruiting?

NCT06331975 is currently completed. Last updated 26 March 2024.

Last reviewed 2024-03-26 · How we verify

NCT06331975

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiomics and Radiogenomics of Non-small Cell Lung Cancer

Completed NA Last updated 26 March 2024

What this trial tests

NA trial testing Radiomic signature in Non Small Cell Lung Cancer in 91 participants. Completed in 14 September 2023.

Timeline

12 June 2018

Primary endpoint
31 January 2023

14 September 2023

Quick facts

Lead sponsor	European Institute of Oncology
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	91
Start date	12 June 2018
Primary completion	31 January 2023
Estimated completion	14 September 2023
Sites	1 location across Italy

Drugs / interventions tested

Radiomic signature

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

European Institute of Oncology

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the radiomic characteristics and a broad range of genetic aberrations in lung adenocarcinomas will be evaluated. Investigators will assess changes in the radiomic and genetic profiles during targeted therapies in a subset of patients harboring treatable mutations. Patients undergoing targeted therapies will also be evaluated for variations in genomic profile and radiomic signature during follow-up

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Radiogenomic approach combining CT-based radiomics and liquid biopsy improves prognostic stratification in patients with advanced NSCLC.
Ranghiero A, Rinaldi L, Netti S, Gaeta A, et al · · 2026 · PMID 42095156 · DOI 10.1016/j.jlb.2026.100470

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other European Institute of Oncology trials

Trials by the same sponsor.

NCT07374809 — IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER · NA · not yet recruiting
NCT07429851 — CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07508319 — Role of the Immune System in Preventing Laryngeal Cancer · recruiting
NCT07180693 — Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06331975 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Institute of Oncology
Last refreshed: 26 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06331975.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing